{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Letetresgene_Autoleucel",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "Human autologous T-lymphocytes transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for the cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 (LAGE-1; Cancer/Testis Antigen 2; CTAG2; CT2), with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, letetresgene autoleucel specifically target and bind to NY-ESO-1/LAGE-1-overexpressing tumor cells. This may result in a cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1/LAGE-1-positive cancer cells. NY-ESO-1 and LAGE-1, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types.",
    "fdaUniiCode": "B5ME4ZU4BS",
    "identifier": "C121379",
    "preferredName": "Letetresgene Autoleucel",
    "semanticType": "Cell",
    "subclassOf": [
      "C129826",
      "C138180",
      "C1962",
      "C28681"
    ],
    "synonyms": [
      "Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794",
      "Autologous T-Cells Expressing Enhanced TCRs Specific for NY-ESO-1/LAGE-1a GSK3377794",
      "Genetically Engineered NY-ESO-1 Specific [c259] T Cells GSK3377794",
      "Genetically Engineered NY-ESO-1/LAGE-1 Specific (c259) T Cells GSK3377794",
      "LETETRESGENE AUTOLEUCEL",
      "Letetresgene Autoleucel",
      "NY-ESO-1c259 T Cells GSK3377794"
    ]
  }
}